Compare
PDS Biotechnology Corp vs Yarrow Bioscience, Inc. vs China Pharma Holdings, Inc. vs Sol-Gel Technologies Ltd.
| Latest fiscal year | PDS Biotechnology Corp PDSB | Yarrow Bioscience, Inc. YARW | China Pharma Holdings, Inc. CPHI | Sol-Gel Technologies Ltd. SLGL |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $570.0K | $4.14M | $19.39M |
| Revenue growth (YoY) | n/a | +13.8% | -8.5% | +68.0% |
| Gross margin | n/a | n/a | -3.2% | n/a |
| Operating margin | n/a | n/m | -78.2% | -38.9% |
| Net margin | n/a | n/m | -76.9% | -31.6% |
| Net income | -$34.50M | -$26.48M | -$3.19M | -$6.13M |
| EPS (Diluted) | -$0.74 | -$0.62 | -$0.74 | -$2.19 |
| Operating cash flow | -$27.75M | -$33.12M | $148.3K | $322.0K |
| Free cash flow | -$27.75M | -$33.12M | $88.9K | $275.0K |
| Cash & equivalents | $26.71M | $24.03M | $345.1K | $11.03M |
| Total assets | $30.49M | $30.16M | $31.00M | $29.92M |
| Total liabilities | $21.24M | $2.40M | $8.26M | $7.11M |
| Shareholders' equity | $9.25M | $27.77M | $22.74M | $22.81M |
| Return on year-end equity | -372.9% | -95.4% | -14.0% | -26.9% |
| Shares outstanding | 54.88M | 33.32M | 15.52M | 2.79M |
Revenue, most recent five fiscal years
| Fiscal year | PDS Biotechnology Corp | Yarrow Bioscience, Inc. | China Pharma Holdings, Inc. | Sol-Gel Technologies Ltd. |
|---|---|---|---|---|
| Latest | n/a | $570.0K Ended 2025-12-31 | $4.14M Ended 2025-12-31 | $19.39M Ended 2025-12-31 |
| 1 year earlier | n/a | $501.0K Ended 2024-12-31 | $4.53M Ended 2024-12-31 | $11.54M Ended 2024-12-31 |
| 2 years earlier | n/a | $424.0K Ended 2023-12-31 | $7.01M Ended 2023-12-31 | $1.55M Ended 2023-12-31 |
| 3 years earlier | n/a | $477.0K Ended 2022-12-31 | $8.10M Ended 2022-12-31 | $3.88M Ended 2022-12-31 |
| 4 years earlier | n/a | $931.0K Ended 2021-12-31 | $9.64M Ended 2021-12-31 | $31.27M Ended 2021-12-31 |